Fidelity Investments

Dianthus Therapeutics is a biotech company operating in stealth mode. It was founded in 2019 and is based in Waltham, Massachusetts.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Provider of counseling and psychiatric services intended to provide mental healthcare. The company offers services to a variety of life issues including depression, anxiety, relationship issues, low self-esteem, trauma and other mental health concerns, ensuring its clients with customized plans for their mental well-being.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CarMax operates medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

Cano Health is a rapidly expanding operator of healthcare centers that emphasizes "Primary Care Plus," aiming to enhance the health and well-being of individuals, families, and communities. The company provides comprehensive primary medical care alongside specialty programs in areas such as Venous Medicine, Arthritis, Allergy, and Weight Loss. With a focus on personalized, value-based care, Cano Health serves approximately 310,000 members through its advanced medical centers located in Miami-Dade and Broward counties. By leveraging technology and a high-touch approach, Cano Health seeks to transform healthcare delivery, improving the overall quality of life for its patients and the communities it serves.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, the company has developed the Globe Mapping and Ablation System, which streamlines AF treatment by integrating single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation into a single catheter. This advanced system aids medical practitioners in diagnosing and treating cardiovascular diseases by providing detailed electrophysiological mapping and the ability to ablate cardiac tissue using radio-frequency energy. Kardium's team comprises experts in medicine, engineering, and research, ensuring a robust foundation for innovation in medical device technology.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.

Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.

Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. Founded in 2016, the company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create dual-function fusion proteins that enhance immune responses against tumors. Its lead product candidate, SL-172154, is currently undergoing a Phase 1 clinical trial for ovarian cancer, designed to inhibit the CD47/SIRPa checkpoint interaction while activating the CD40 costimulatory receptor. Additionally, Shattuck collaborates with Takeda Pharmaceuticals on SL-279252, also in Phase 1 trials, which targets the PD-1/PD-L1 interaction and activates the OX40 receptor to improve anti-tumor immunity. Through its innovative approaches, Shattuck Labs aims to advance the field of immuno-oncology and provide effective treatments for various malignancies.

Alignment Healthcare is dedicated to transforming the complex and confusing process of medical treatment so that every link in the healthcare continuum becomes more efficient, productive and effective. The company partners with providers, health plans and hospitals to create a seamless, fast and easy-to-navigate healthcare experience, which results in happier, healthier and more satisfied patients. Based in Irvine, California, Alignment Healthcare provides partners with an end-to-end continuous care program, including clinical care coordination, risk management capabilities, and IT enablement

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

10X Genomics is a life science technology company that specializes in developing and selling instruments, consumables, and software for analyzing biological systems. Headquartered in Pleasanton, California, the company offers a range of products, including chromium instruments, microfluidic chips, reagents, and other consumables. Its advanced single-cell solutions allow researchers to measure gene expression, immune profiling, epigenetics, and cellular heterogeneity, providing insights into the physical organization of DNA and gene activity on a cell-by-cell basis. Additionally, the Visium spatial gene expression solution enables the measurement of spatial gene expression patterns across tissue samples. 10X Genomics serves a diverse clientele, including academic institutions, government agencies, and biopharmaceutical companies, and has a presence in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was founded in 2012 and rebranded from 10X Technologies, Inc. in November 2014.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Think Research is a Canada-based healthcare technology company that specializes in providing knowledge-based tools and clinical content to clinicians at the point of care. Founded in 2006, the company addresses the complex challenges faced by healthcare organizations, such as health system reform and quality improvement, by offering practical and cost-effective solutions. Its services include knowledge translation, partner applications like eMED-PASS and how2track, and various platforms designed to enhance clinical practice. By utilizing ontologic and semantic-based artificial intelligence and machine learning, Think Research improves the utilization of patient data. The company delivers its Software-as-a-Service solutions globally to a diverse range of clients, including hospitals, health regions, healthcare professionals, and government entities, thereby facilitating better healthcare outcomes across various care settings.

Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Kaleido Biosciences is a clinical-stage healthcare company based in Lexington, Massachusetts, dedicated to developing microbiome metabolic therapies (MMTs) aimed at treating various diseases and improving human health. Founded in 2015, the company is advancing a diverse pipeline of MMT candidates targeting conditions such as urea cycle disorders, hepatic encephalopathy, multi-drug resistant infections, cardiometabolic and liver diseases, and immune oncology. Kaleido employs a unique, chemistry-driven approach to harness the microbiome's potential, focusing on modulating its metabolic output and profile by influencing the existing microbial functions. The company has established collaborations with notable institutions, including Gustave Roussy Cancer Center and Washington University School of Medicine, to further explore the applications of MMTs in immuno-oncology and other health conditions.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

10X Genomics is a life science technology company that specializes in developing and selling instruments, consumables, and software for analyzing biological systems. Headquartered in Pleasanton, California, the company offers a range of products, including chromium instruments, microfluidic chips, reagents, and other consumables. Its advanced single-cell solutions allow researchers to measure gene expression, immune profiling, epigenetics, and cellular heterogeneity, providing insights into the physical organization of DNA and gene activity on a cell-by-cell basis. Additionally, the Visium spatial gene expression solution enables the measurement of spatial gene expression patterns across tissue samples. 10X Genomics serves a diverse clientele, including academic institutions, government agencies, and biopharmaceutical companies, and has a presence in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was founded in 2012 and rebranded from 10X Technologies, Inc. in November 2014.

Soundbite Medical Solutions Inc. is a cardiovascular medical technology company based in Montreal, Canada, specializing in the development and commercialization of innovative medical devices. Founded in 2013, the company focuses on creating a proprietary wire-based device and generator console that utilizes shockwave energy to treat chronic total occlusions (CTOs) within the cardiovascular system. This technology is designed to enhance vessel preparation for patients suffering from peripheral artery disease (PAD) and coronary artery disease (CAD), which collectively impact over 20 million individuals in the United States. Soundbite Medical Solutions aims to improve treatment outcomes for these patients through its advanced therapeutic solutions.

Imagia Cybernetics Inc. is a Montreal-based company that specializes in medical image analysis solutions aimed at cancer detection and management. The company focuses on early detection and quantification of cancer changes, which is crucial for improving patient outcomes. Imagia's Artificial Clinical Intelligence Platform delivers timely insights into primary tumors and metastasis, thereby personalizing the cancer care continuum for patients. Utilizing a unique approach called Deep Radiomics, which combines radiomics and deep learning, the platform analyzes routine clinical imaging data to identify robust biomarkers that can predict patient outcomes. By leveraging advancements in artificial intelligence and federated learning, Imagia enhances the capabilities of clinicians, enabling them to conduct predictive, diagnostic, and prescriptive analytics while maintaining data privacy.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Medibio Limited is a health technology company focused on the research, development, and commercialization of mental health solutions aimed at the screening, diagnosis, monitoring, and management of depression and related disorders. Operating in Australia and the United States, the company provides mental well-being solutions for businesses and develops products for healthcare providers. Medibio has created an objective test based on circadian heart rate variability, which utilizes proprietary algorithms to deliver quantifiable measures for clinical diagnosis. This test is undergoing validation in clinical studies conducted by reputable institutions, including Johns Hopkins University School of Medicine and The University of Ottawa, to support its application for FDA approval. Additionally, Medibio's technology is applicable in workplace stress and well-being markets, as well as in wearable technology and app development. Originally founded as BioProspect Limited in 1987, Medibio rebranded in 2014 and operates offices in Melbourne and the United States.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Home Dialysis Plus, Ltd. provides home hemodialysis solutions to patients and their healthcare providers. Its dialysis system enables hemodialysis treatment in the homes of patients. Home Dialysis Plus, Ltd. was founded in 2003 and is based in Portland, Oregon.

Imagia Cybernetics Inc. is a Montreal-based company that specializes in medical image analysis solutions aimed at cancer detection and management. The company focuses on early detection and quantification of cancer changes, which is crucial for improving patient outcomes. Imagia's Artificial Clinical Intelligence Platform delivers timely insights into primary tumors and metastasis, thereby personalizing the cancer care continuum for patients. Utilizing a unique approach called Deep Radiomics, which combines radiomics and deep learning, the platform analyzes routine clinical imaging data to identify robust biomarkers that can predict patient outcomes. By leveraging advancements in artificial intelligence and federated learning, Imagia enhances the capabilities of clinicians, enabling them to conduct predictive, diagnostic, and prescriptive analytics while maintaining data privacy.

Heal, Inc. operates an on-demand healthcare platform that connects patients with licensed, background-checked pediatricians and family doctors for house calls and telemedicine services. Founded in 2014 and based in Los Angeles, the company offers its services across several states, including California, Georgia, Maryland, New Jersey, New York, Virginia, Washington, and the District of Columbia. Patients can schedule appointments through Heal's mobile application available on both the App Store and Google Play. The service is designed to provide timely and convenient medical care for various needs, including urgent care, primary care, and preventive care, with costs typically around $99 or covered by select insurance co-pays. Heal aims to enhance the patient experience by making quality healthcare more accessible while ensuring that doctors can practice medicine in a fulfilling way.

Medibio Limited is a health technology company focused on the research, development, and commercialization of mental health solutions aimed at the screening, diagnosis, monitoring, and management of depression and related disorders. Operating in Australia and the United States, the company provides mental well-being solutions for businesses and develops products for healthcare providers. Medibio has created an objective test based on circadian heart rate variability, which utilizes proprietary algorithms to deliver quantifiable measures for clinical diagnosis. This test is undergoing validation in clinical studies conducted by reputable institutions, including Johns Hopkins University School of Medicine and The University of Ottawa, to support its application for FDA approval. Additionally, Medibio's technology is applicable in workplace stress and well-being markets, as well as in wearable technology and app development. Originally founded as BioProspect Limited in 1987, Medibio rebranded in 2014 and operates offices in Melbourne and the United States.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.

Adherium (previously known as Nexus6) is a privately owned developer and manufacturer of solutions that help patients and their healthcare professionals monitor and increase patient adherence to prescribed therapies, leading to improved disease management and reduced healthcare costs.

10X Genomics is a life science technology company that specializes in developing and selling instruments, consumables, and software for analyzing biological systems. Headquartered in Pleasanton, California, the company offers a range of products, including chromium instruments, microfluidic chips, reagents, and other consumables. Its advanced single-cell solutions allow researchers to measure gene expression, immune profiling, epigenetics, and cellular heterogeneity, providing insights into the physical organization of DNA and gene activity on a cell-by-cell basis. Additionally, the Visium spatial gene expression solution enables the measurement of spatial gene expression patterns across tissue samples. 10X Genomics serves a diverse clientele, including academic institutions, government agencies, and biopharmaceutical companies, and has a presence in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was founded in 2012 and rebranded from 10X Technologies, Inc. in November 2014.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Dr. Lal PathLabs, founded in 1949 by Dr. S.K. Lal, a pioneer in pathology, has established itself as a leading clinical pathology laboratory in India. Originally the first of its kind in Delhi and Northern India, the organization has expanded its services to include comprehensive diagnostic offerings in pathology and radiology. Dr. Lal PathLabs operates multiple laboratories that conduct a wide range of tests across various disciplines such as biochemistry, hematology, histopathology, microbiology, immunology, and virology. These diagnostic services play a crucial role in disease prevention, monitoring, and treatment, ultimately contributing to improved health outcomes. While the company primarily generates its revenue in India, it also operates in several other countries, reflecting its growing international presence in the healthcare sector.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.